Cargando…

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

Cerebrospinal fluid and positron emission tomography biomarkers accurately predict an underlying Alzheimer's disease (AD) pathology; however, they represent either invasive or expensive diagnostic tools. Therefore, a blood-based biomarker like plasma amyloid beta (Aβ) that could correlate with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toledo, Jon B, Shaw, Leslie M, Trojanowski, John Q
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706955/ https://www.ncbi.nlm.nih.gov/pubmed/23470128 http://dx.doi.org/10.1186/alzrt162

Ejemplares similares

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging
por: Abner, Erin L., et al.
Publicado: (2016)

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
por: Brand, Abby L., et al.
Publicado: (2022)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease
por: Jack, Clifford R., et al.
Publicado: (2010)

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
por: Kang, Ju-Hee, et al.
Publicado: (2014)

Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease
por: Guo, Tengfei, et al.
Publicado: (2020)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

The elusive biomarker
por: Huntingford, Simone, et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Quantification and targeting of elusive neurotoxic amyloid oligomers
por: Bhatt, Nemil, et al.
Publicado: (2022)

CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
por: Hansson, Oskar, et al.
Publicado: (2018)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure
por: Yang, YoungSoon, et al.
Publicado: (2018)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI
por: Toledo, Jon B., et al.
Publicado: (2013)

Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease
por: Kim, Young Hyo, et al.
Publicado: (2019)

Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment
por: Toledo, Jon B, et al.
Publicado: (2014)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Erratum: Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure
por: Yang, YoungSoon, et al.
Publicado: (2023)

Dietary Glycemic Load and Plasma Amyloid-β Biomarkers of Alzheimer’s Disease
por: Gentreau, Mélissa, et al.
Publicado: (2022)

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans
por: Moon, Sohee, et al.
Publicado: (2021)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy
por: de Kort, Anna M., et al.
Publicado: (2023)

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
por: Sharma, Abhinav, et al.
Publicado: (2023)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease
por: Trombetta, Bianca A., et al.
Publicado: (2018)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia
por: Berlyand, Yosef, et al.
Publicado: (2016)

The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer's Disease
por: Sun, Hao-Lun, et al.
Publicado: (2018)

Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers()()
por: Da, Xiao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dqqqsukjqsd42sflrguoe5nv7c